Introduction: Neonatal sepsis is a leading cause of mortality in Cameroon. Diagnosis still relies heavily on the detection of C reactive protein (CRP) levels, whereas other biomarkers like interleukin 6 (IL-6), could improve the early diagnosis of neonatal sepsis in comparison to CRP. This study aimed to assess the efficacy and feasibility of IL-6 ELISA as an early diagnostic tool within a Cameroonian context with the hope of its applicability in other poor income settings and in other diseases like COVID-19. Methods: We enrolled thirty-two (32) neonates equally distributed between a septic group (including infants with risk factors and clinical signs of sepsis) and a control group (infants without clinical signs of infections) in the study. We performed Full Blood Count, C-reactive protein and IL-6 ELISA on all blood samples. Thirty-five (35) medical personnel were interviewed in order to assess acceptability, practicality (cost and duration) and a limited-efficacy of IL-6 ELISA testing at the Bafoussam regional Hospital, Cameroon. Results: The mean age of participants was 2.81 days. IL-6 ELSIA showed a sensitivity, specificity, positive predictive value and negative predictive value of 56.20%, 100%, 100% and 69.56% respectively while CRP was reported to be highly specific (81.25%). Despite a longer testing time of IL-6 ELISA compared to CRP (p = 0.0385), the IL-6 was acceptable (p = 0.008), affordable (p = 0.006) and could be promising for use within this poor setting. Conclusion: Though we did not see a strong correlation between its levels and the apparition of disease, IL-6 ELISA testing was feasible as a highly specific marker for an early diagnosis neonatal sepsis in Bafoussam, and could acceptably be used as an early diagnostic marker for other diseases like COVID-19 within that context.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.